(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Chicago reports first rabies-positive dog in 61 years. What we know. - 2Mussolini's summer villa on Adriatic coast sold for €1.2 million
- 3West Bank man indicted for extortion, impersonation of IAF pilot, Mossad agent, illegal entry
- 4NASA's Perseverance Mars rover could break the record for miles driven on another planet
- 5Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- Artemis II shares new lunar images while more than halfway to the moon
- Fossils unearthed in Morocco are first from little-understood period of human evolution
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- Ten Awesome Authentic Realities That Will Leave You Interested
- Toyota Just Electrified a Pickup Legend, but It Won’t Be Cheap
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- Turkey key underlying issue as Israel, Greece, Cyprus hold summit
